153 related articles for article (PubMed ID: 31738620)
41. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments.
Menéndez-Arias L
Antiviral Res; 2013 Apr; 98(1):93-120. PubMed ID: 23403210
[TBL] [Abstract][Full Text] [Related]
42. Evolution of HIV-1 multidrug-resistant genotypes during combination therapy and after the cessation of antiretroviral drugs.
Yahi N; Tourrès C; Tivoli N; Colson P; Dhiver C; Quinson AM; Tamalet C
AIDS; 2000 Dec; 14(18):2943-5. PubMed ID: 11153678
[No Abstract] [Full Text] [Related]
43. Should patients with drug-resistant HIV-1 continue to receive antiretroviral therapy?
Frenkel LM; Mullins JI
N Engl J Med; 2001 Feb; 344(7):520-2. PubMed ID: 11172196
[No Abstract] [Full Text] [Related]
44. HIV antiretroviral drug resistance in Africa.
Nkengasong JN; Adje-Toure C; Weidle PJ
AIDS Rev; 2004; 6(1):4-12. PubMed ID: 15168736
[TBL] [Abstract][Full Text] [Related]
45. Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.
Sierra-Aragón S; Walter H
Intervirology; 2012; 55(2):84-97. PubMed ID: 22286875
[TBL] [Abstract][Full Text] [Related]
46. Rapid HIV-1 genotyping assay for the detection of capsid mutations.
Margot N; Naik V; Nekkalapudi A; Boopathy A; Falkard B; Callebaut C
J Med Virol; 2023 Dec; 95(12):e29292. PubMed ID: 38063404
[TBL] [Abstract][Full Text] [Related]
47. Discovery of phenylalanine derivatives as potent HIV-1 capsid inhibitors from click chemistry-based compound library.
Wu G; Zalloum WA; Meuser ME; Jing L; Kang D; Chen CH; Tian Y; Zhang F; Cocklin S; Lee KH; Liu X; Zhan P
Eur J Med Chem; 2018 Oct; 158():478-492. PubMed ID: 30243152
[TBL] [Abstract][Full Text] [Related]
48. Adherence to antiretroviral therapy: how much is enough?
Gulick RM
Clin Infect Dis; 2006 Oct; 43(7):942-4. PubMed ID: 16941381
[No Abstract] [Full Text] [Related]
49. Specific Inhibitors of HIV Capsid Assembly Binding to the C-Terminal Domain of the Capsid Protein: Evaluation of 2-Arylquinazolines as Potential Antiviral Compounds.
Machara A; Lux V; Kožíšek M; Grantz Šašková K; Štěpánek O; Kotora M; Parkan K; Pávová M; Glass B; Sehr P; Lewis J; Müller B; Kräusslich HG; Konvalinka J
J Med Chem; 2016 Jan; 59(2):545-58. PubMed ID: 26685880
[TBL] [Abstract][Full Text] [Related]
50. Antiretroviral Resistance Mutations (revised April 2001).
;
HIV Clin Trials; 2001; 2(4):346-55. PubMed ID: 11590539
[No Abstract] [Full Text] [Related]
51. Antiretroviral resistance testing policy in England's north Thames HIV units: a survey of current practice.
Mackie N; Brook G; Dale A; Tomlinson D
AIDS; 2000 Jul; 14(10):1458-60. PubMed ID: 10930166
[No Abstract] [Full Text] [Related]
52. Implications of antiretroviral resistance on viral fitness.
Nijhuis M; Deeks S; Boucher C
Curr Opin Infect Dis; 2001 Feb; 14(1):23-8. PubMed ID: 11979111
[TBL] [Abstract][Full Text] [Related]
53. Roles of Capsid-Interacting Host Factors in Multimodal Inhibition of HIV-1 by PF74.
Saito A; Ferhadian D; Sowd GA; Serrao E; Shi J; Halambage UD; Teng S; Soto J; Siddiqui MA; Engelman AN; Aiken C; Yamashita M
J Virol; 2016 Jun; 90(12):5808-5823. PubMed ID: 27076642
[TBL] [Abstract][Full Text] [Related]
54. Antiretroviral resistance testing comes of age.
Hammer SM; Pedneault L
Antivir Ther; 2000 Mar; 5(1):23-6. PubMed ID: 10846589
[No Abstract] [Full Text] [Related]
55. Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: structure-activity relationships (SAR) of the C3-phenyl moiety.
Fader LD; Landry S; Goulet S; Morin S; Kawai SH; Bousquet Y; Dion I; Hucke O; Goudreau N; Lemke CT; Rancourt J; Bonneau P; Titolo S; Amad M; Garneau M; Duan J; Mason S; Simoneau B
Bioorg Med Chem Lett; 2013 Jun; 23(11):3401-5. PubMed ID: 23601710
[TBL] [Abstract][Full Text] [Related]
56. Current insights into reverse transcriptase inhibitor-associated resistance.
Wainberg MA; White AJ
Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
[No Abstract] [Full Text] [Related]
57. Antiviral inhibition of the HIV-1 capsid protein.
Tang C; Loeliger E; Kinde I; Kyere S; Mayo K; Barklis E; Sun Y; Huang M; Summers MF
J Mol Biol; 2003 Apr; 327(5):1013-20. PubMed ID: 12662926
[TBL] [Abstract][Full Text] [Related]
58. Candidate microbicides and their mechanisms of action.
Herrera C; Shattock RJ
Curr Top Microbiol Immunol; 2014; 383():1-25. PubMed ID: 23612992
[TBL] [Abstract][Full Text] [Related]
59. Anti-HIV drug development--an overview.
Pereira CF; Paridaen JT
Curr Pharm Des; 2004; 10(32):4005-37. PubMed ID: 15579085
[TBL] [Abstract][Full Text] [Related]
60. New developments in HIV drug resistance.
Cane PA
J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
